BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.14% | 0.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.14% | 0.36% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -2.14% | 0.36% | |||
| SG&A Expenses | -49.54% | -17.33% | |||
| Depreciation & Amortization | -1.88% | 0.95% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -46.64% | -1.26% | |||
| Operating Income | 49.63% | 1.37% | |||
| Income Before Tax | 40.39% | 11.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.39% | 11.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.39% | 11.90% | |||
| EBIT | 49.63% | 1.37% | |||
| EBITDA | 50.01% | 1.45% | |||
| EPS Basic | 93.18% | 12.00% | |||
| Normalized Basic EPS | 92.86% | 9.68% | |||
| EPS Diluted | 93.18% | 12.00% | |||
| Normalized Diluted EPS | 92.86% | 9.68% | |||
| Average Basic Shares Outstanding | 874.01% | 0.00% | |||
| Average Diluted Shares Outstanding | 874.01% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||